Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $200M Series A (Mar 2026) at $2B+ valuation led by AON Consulting. 91%+ medication adherence. GLP-1 benefits platform for employers. Linda Yaccarino CEO.
eMed is a GLP-1 and metabolic health benefits platform built specifically for employer-sponsored health plans, the fastest-growing category in US workplace benefits. The company raised $200 million in Series A financing in March 2026 at a $2 billion+ valuation led by AON Consulting, with backing from Linda Yaccarino (former Twitter/X CEO, now eMed CEO) and Tom Brady. Claiming 91%+ medication adherence rates, eMed positions itself as the most effective GLP-1 benefits program available to employers.
Raised $50M equity ($106M total). Processes 5.5M prior authorizations/year for 15M health plan members and 420,000 providers. CMS 2026 deadline a direct growth catalyst.
Cohere Health (not affiliated with the AI company Cohere) is a prior authorization intelligence platform operating on the payer side of healthcare — a differentiated position from provider-facing prior auth tools. The company has raised $106 million in total equity financing and processes 5.5 million prior authorizations annually covering 15 million health plan members and 420,000 provider relationships for its health plan customers.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.